Treating gastro-intestinal disorders and emesis with n-(heterocyclic substituted) benzamides

A compound according to claim 26, wherein

• R.sub.1 is alkoxy of 1 to 6 carbon atoms;
• R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, CF.sub.3, hydroxy, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 7 carbon atoms, amino, amino substituted by one or two alkyl moieties of 1 to 6 carbon atoms, alkanoylamino of 2 to 7 carbon atoms, aminosulphone, aminosulphone substituted by one or two alkyl moieties of 1 to 6 carbon atoms, alkylsulphone of 1 to 6 carbon atoms or nitro;
• m+n is 2 or 3, and m is 1, 2 or 3 and n is 0, 1 or 2;
• P is 0 or 1;
• R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl or phenyl-alkyl of 1 to 6 carbon atoms in the alkyl moiety, said phenyl or said phenyl-alkyl being nuclear-unsubstituted or nuclear-substituted by alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, CF.sub.3 or halogen, and R.sub.5 is hydrogen;
• or R.sub.4 and R.sub.5 are attached to two adjacent carbon atoms and form together with these two carbon atoms a fused benzene ring, which benzene ring is unsubstituted or substituted by alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, CF.sub.3 or halogen.

A pharmaceutical composition useful for the treatment of disorders of the gastro-intestional function and emesis which comprises a therapeutically effective amount of a compound of the formula (I) ##STR51## or a pharmaceutically acceptable salt thereof wherein R.sub.1 is alkoxy of 1 to 6 carbon atoms;

• R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, CF.sub.3, hydroxy, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 7 carbon atoms, amino, amino substituted by one or two alkyl moieties of 1 to 6 carbon atoms, alkanoylamino of 2 to 7 carbon atoms, aminocarbonyl or aminosulphone unsubstituted or substituted by one or two alkyl moieties of 1 to 6 carbon atoms, alkylsulphone of 1 to 6 carbon atoms or nitro;
• X is either a nitrogen atom, in which case m+n is 3 to 5, m is 2 to 4 and n is 1 to 3;
• or X is CH in which case m+n is 2 to 5, m is 1 to 5, and n is 0 to 4;
• p is 0 to 3;
• R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl or phenyl-alkyl of 1 to 6 carbon atoms in the alkyl moiety, said phenyl or phenyl-alkyl being nuclear-unsubstituted or nuclear substituted by alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, CF.sub.3 or halogen, and R.sub.5 is hydrogen;
• or R.sub.4 and R.sub.5 are attached to two adjacent carbon atoms and form together with these two adjacent carbon atoms, a fused benzene ring, which benzene ring is unsubstituted or substituted by alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, CF.sub.3 or halogen, in combination with a pharmaceutically acceptable carrier.

A method of treating disorders of the gastro-intestinal function and emesis in humans and animals which comprises administering to a human or animal in need thereof a therapeutically effective amount of a compound of the formula (I) ##STR58## or a pharmaceutically acceptable salt thereof wherein R.sub.1 is alkoxy of 1 to 6 carbon atoms;

• R.sub.2 and R.sub.3 are the same or different and are hydrogen, halogen, CF.sub.3, hydroxy, alkoxy of 1 to 6 carbon atoms, alkanoyl of 2 to 7 carbon atoms, amino, amino substituted by one or two alkyl moieties of 1 to 6 carbon atoms, alkanoylamino of 2 to 7 carbon atoms, aminocarbonyl or aminosulphone unsubstituted or substituted by one or two alkyl moieties of 1 to 6 carbon atoms, alkylsulphone of 1 to 6 carbon atoms or nitro;
• X is either a nitrogen atom, in which case m+n is 3 to 5, m is 2 to 4 and n is 1 to 3;
• or X is CH in which case m+n is 2 to 5, m is 1 to 5, and n is 0 to 4;
• p is 0 to 3;
• R.sub.4 is hydrogen, alkyl of 1 to 6 carbon atoms, phenyl or phenyl-alkyl of 1 to 6 carbon atoms in the alkyl moiety, said phenyl or phenyl-alkyl being nuclear-unsubstituted or nuclear substituted by alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, CF.sub.3 or halogen, and R.sub.5 is hydrogen;
• or R.sub.4 and R.sub.5 are attached to two adjacent carbon atoms and form together with these two adjacent carbon atoms, a fused benzene ring, which benzene ring is unsubstituted or substituted by alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 carbon atoms, CF.sub.3 or halogen, in combination with a pharmaceutically acceptable carrier.